Piper Sandler raised the firm’s price target on Verona Pharma to $36 from $31 and keeps an Overweight rating on the shares. The firm says Verona remains one of its 2024 names with what it believes to be the lowest clinical risk and highest probability of success for approval for ensifentrine in COPD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
